The KCa2 Channel Inhibitor AP14145, But Not Dofetilide or Ondansetron, Provides Functional Atrial Selectivity in Guinea Pig Hearts

Kirchhoff, Jeppe Egedal; Skarsfeldt, Mark; Muthukumarasamy, Kalai Mangai; Simó-Vicens, Rafel; Bomholtz, Sofia Hammami; Abildgaard, Lea; Jespersen, Thomas; Sørensen, Ulrik S; Grunnet, Morten; Bentzen, Bo Hjorth; Diness, Jonas Goldin

Published in:
Frontiers in Pharmacology

DOI:
10.3389/fphar.2019.00668

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Kirchhoff, J. E., Skarsfeldt, M., Muthukumarasamy, K. M., Simó-Vicens, R., Bomholtz, S. H., Abildgaard, L., ... Diness, J. G. (2019). The KCa2 Channel Inhibitor AP14145, But Not Dofetilide or Ondansetron, Provides Functional Atrial Selectivity in Guinea Pig Hearts. Frontiers in Pharmacology, 10, [668]. https://doi.org/10.3389/fphar.2019.00668
The $K_{Ca2}$ Channel Inhibitor AP14145, But Not Dofetilide or Ondansetron, Provides Functional Atrial Selectivity in Guinea Pig Hearts

Jeppe Egedal Kirchhoff$^1$, Mark Alexander Skarsfeldt$^2$, Kalai Mangai Muthukumarasamy$^2$, Rafel Simó-Vicens$^{1,2}$, Sofia Hammami Bomholtz$^{1,2}$, Lea Abildgaard$^1$, Thomas Jespersen$^2$, Ulrik S. Sørensen$^1$, Morten Grunnet$^1$, Bo Hjorth Bentzen$^{1,2}$ and Jonas Goldin Diness$^1$

$^1$Acesion Pharma, Copenhagen, Denmark, $^2$Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Background and Purpose: Prolongation of cardiac action potentials is considered antiarrhythmic in the atria but can be proarhythmic in ventricles if the current carried by Kv11.1-channels ($I_{Kr}$) is inhibited. The current mediated by $K_{Ca2}$-channels, $I_{KCa}$, is considered a promising new target for treatment of atrial fibrillation (AF). Selective inhibitors of $I_{Kr}$ (dofetilide) and $I_{KCa}$ (AP14145) were used to compare the effects on ventricular and atrial repolarization. Ondansetron, which has been reported to be a potent blocker of both $I_{Kr}$ and $I_{KCa}$, was included to examine its potential atrial antiarrhythmic properties.

Experimental Approach: The expression of $K_{Ca2}$- and Kv11.1-channels in the guinea pig heart was investigated using quantitative polymerase chain reaction (qPCR). Whole-cell patch clamp technique was used to investigate the effects of dofetilide, AP14145, and ondansetron on $I_{KCa}$ and/or $I_{Kr}$. The effect of dofetilide, AP14145, and ondansetron on atrial and ventricular repolarization was investigated in isolated hearts. A novel atrial paced in vivo guinea pig model was further validated using AP14145 and dofetilide.

Key Results: AP14145 increased the atrial effective refractory period (AERP) without prolonging the QT interval with Bazett’s correction for heart rate (QTcB) both ex vivo and in vivo. In contrast, dofetilide increased QTcB and, to a lesser extent, AERP in isolated hearts and prolonged QTcB with no effects on AERP in the in vivo guinea pig model. Ondansetron did not inhibit $I_{KCa}$, but did inhibit $I_{Kr}$ in vitro. Ondansetron prolonged ventricular, but not atrial repolarization ex vivo.

Conclusion and Implications: $I_{KCa}$ inhibition by AP14145 selectively increases atrial repolarization, whereas $I_{Kr}$ inhibition by dofetilide and ondansetron increases ventricular repolarization to a larger extent than atrial repolarization.

Keywords: arrhythmia (heart rhythm disorders), dofetilide, ondansetron, AP14145, QT prolongation
INTRODUCTION

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia and is associated with reduced quality of life and increased mortality and morbidity (Heering et al., 2006; Piccini et al., 2012). AF is often treated with antiarrhythmic drugs that affect the electrical properties of ion channels in the heart (Zimnethaum, 2012). Class III antiarrhythmic compounds exert their effects by decreasing cardiac K+ currents leading to delayed repolarization and a concomitant increased effective refractory period. Prolonging the atrial effective refractory period (AERP) is antiarrhythmic, whereas drug induced prolongation of the ventricular repolarization that manifests as prolongation of the QT interval on a surface ECG is a risk marker for potentially lethal ventricular arrhythmias such as torsades de pointes for a wide range of drugs. For the majority of these compounds the QT prolongation is caused by inhibition of the rapidly activating delayed rectifier potassium current I\textsubscript{Kr} carried by the K\textsubscript{11.1} (also known as the hERG) channel (Redfearn et al., 2003). The QT interval corrected for heart rate (HR) using Bazett’s formula (QTcB) is therefore used as a surrogate marker for proarrhythmicitic, albeit an imperfect one since not all drugs that prolong the QTcB are proarrhythmic (Piccini et al., 2009).

Dofetilide is an archetypical class III antiarrhythmic that selectively blocks I\textsubscript{Kr} (Roukz and Saliba, 2007). Although fairly effective at treating AF, the use of classical class III antiarrhythmic compounds has been limited by the risk of inducing potentially lethal ventricular arrhythmias (Waldo et al., 1996). During the last decades, substantial antiarrhythmic effects in normal and remodeled atria, without adverse effects in the ventricles, have therefore been a sought-after therapeutic goal (Grunnet et al., 2012).

AP14145 inhibits the K\textsubscript{c2} channels, also known as small conductance Ca\textsuperscript{2+}-activated K+, or SK channels (Diness et al., 2017; Simó-Vicens et al., 2017a). The current mediated by this channel (I\textsubscript{SKCa}) has emerged as a promising new target for AF treatment, because inhibition of this current can apparently prolong atrial repolarization without affecting the ventricular repolarization, thereby limiting the risk of ventricular adverse effects (Xu et al., 2003; Diness et al., 2010; Diness et al., 2017; Qi et al., 2013). Ondansetron is an antagonist of 5-HT\textsubscript{3} receptors in the CNS and is used as an antiemetic. It has been reported to block both I\textsubscript{Kr} and I\textsubscript{SKCa} at nanomolar concentrations (Kuryshhev et al., 2000; Ko et al., 2018). Three subtypes of K\textsubscript{c2} channels, K\textsubscript{c2.1}, K\textsubscript{c2.2}, and K\textsubscript{c2.3}, carry the I\textsubscript{SKCa} current. The K\textsubscript{c2.2} and K\textsubscript{c2.3} subtypes are predominantly expressed in the human atria (Skalsbye et al., 2014) and have been directly linked to human AF (Ellinor et al., 2010; Ellinor et al., 2012; Christophersen et al., 2017).

In this study, we directly compare the effects on surrogate markers for pro- and antiarrhythmicitic, prolongation of QTcB and AERP of a classical, and an atrial selective class III antiarrhythmic; dofetilide and AP14145. We also test the effects of ondansetron on these parameters in order to investigate whether ondansetron can act as an atrial selective class III antiarrhythmic.

In order to investigate the effects of dofetilide, ondansetron, and AP14145 on both AERP and QTcB we tested the compounds in Langendorff perfused guinea pig hearts.

A novel closed chest in vivo guinea pig model was also developed. In this model a pacing catheter was placed in the right atrium, making it possible to investigate both AERP and QTcB as surrogate markers for anti- and proarrhythmiciticy of new chemical entities in a small animal in vivo model. Both AP14145 and dofetilide were tested in this model to examine the translatability of the Langendorff heart to an in vivo setting.

MATERIALS AND METHODS

This study was carried out in accordance with the recommendations of Danish guidelines for animal experiments according to the European Commission Directive 86/609/EEC, Danish Ministry of Justice. The protocol was approved by the Danish Ministry of Justice (license no. 2016-15-0201-00850).

Drugs and Solutions

AP14145 was supplied by Acesion Pharma. Dofetilide was purchased at Sigma-Aldrich (St. Louis, USA) for the Langendorff and Hello Bio (Bristol, UK) for the closed chest in vivo experiments. Ondansetron was purchased at Sigma-Aldrich (St. Louis, USA). For the Langendorff perfused heart experiments the compounds were dissolved in DMSO to make stock solutions and diluted to the final concentration in the Krebs-Henseleit buffer during the experiments. The final concentration of DMSO never exceeded 0.3% in the buffer. For the closed chest experiments, the compounds were first dissolved in PEG-400 and then diluted to a 50% saline and 50% PEG-400 solution.

For patch clamp experiments, dofetilide, ondansetron, and AP14145 were solubilized in pure DMSO (Sigma-Aldrich, Germany) at 10 mM and bicuculline methiodide (Sigma-Aldrich, Germany) at 100-mM stock solutions. These stock solutions were stored at −20°C and aliquots were solubilized at the desired concentration on the day of the experiment.

The K\textsubscript{c2.2} manual patch-clamp experiments and K\textsubscript{c2.2}/K\textsubscript{c2.3} QPatch experiments were conducted using symmetrical K+ solutions. The extracellular solution contained (in mM) 0.1 CaCl\textsubscript{2}, 3 MgCl\textsubscript{2}, 154 KCl, 10 HEPES, and 10 glucose (pH = 7.4 and 285–295 mOsm). The intracellular solution contained (in mM) 8.106 CaCl\textsubscript{2} (final free Ca\textsuperscript{2+} concentration of 400 nM), 1,167 MgCl\textsubscript{2}, 10 EGTA, 108 KCl, 10 HEPES, 31.25/10 KOH/EGTA, and 15 KOH (pH = 7.2).

The effect of ondansetron on I\textsubscript{SKCa} was studied by adding increasing concentration of drug (in µM: 0.1, 0.3, 1, 3, 10, and 30). Bicuculline methiodide was used as a positive control for K\textsubscript{c2} specific current at the beginning and the end of the experiment.

For the K\textsubscript{11.1} experiments conducted on the automated QPatch machine, the extracellular solution contained (in mM) 145 NaCl, 4 KCl, 2 CaCl\textsubscript{2}, 1 MgCl\textsubscript{2}, 10 HEPES, and 10 glucose (pH = 7.4 and 305 mOsm adjusted with sucrose). The intracellular solution contained (in mM) 120 KCl, 31.25/10 KOH/EGTA, 5.4 CaCl\textsubscript{2}, 1.75 MgCl\textsubscript{2}, 4 mM Na\textsubscript{2}ATP, and 10 HEPES (pH = 7.2 and 285–296 mOsm adjusted with sucrose). Recordings were made before and after application of drug. To establish a half maximal inhibitory concentration (IC\textsubscript{50}) value, increasing concentration of drugs were applied: Dofetilide (in nM: 10, 25, 50, 100, 250, and 500), AP14145 (in µM: 1, 3, 10, 30, and 100), and ondansetron (in µM: 3, 10, 30, 60, 100, and 300). At the end of the experiment, 500 nM
dofetilide was added as a reference drug, and the obtained current level during application of dofetilide was used as the maximal inhibitory response.

**In Vitro Electrophysiology**

**Cell Culture and Cell Preparation for Manual Patch Clamp**

To study the effect of ondansetron on I\(_{KCa}\) wild-type HEK293 cells transiently co-transfected with hK\(_{a-2.2}\) and eGFP plasmid DNAs using standard lipofectamine (Thermo Fisher, USA) protocols. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM1965, Thermo Fisher, USA) supplemented with 26.2 mM NaHCO\(_3\), 25 mM HEPES, 10 ml L\(^{-1}\) Glutamax (Gibco, USA), 10% fetal bovine serum (BioWest, France), and 100 U ml\(^{-1}\) of penicillin/streptomycin (Sigma, Germany); 1 to 2 days after the transfection, patch clamp experiments were conducted. On the day of the experiment, cells were detached from the flask using 1 ml of Detachin (Amsbio, United Kingdom) and plated on 0.5 mm Ø coverslips.

**Cell Culture and Preparation for QPatch Experiments**

The effect of ondansetron on I\(_{KCa}\) was studied in HEK293 cells stably expressing either hK\(_{a-2.2}\) or hK\(_{a-2.3}\) obtained from NeuroSearch A/S. The cell lines were established as described previously (Strobaek et al., 2004). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM1965, Thermo Fisher, USA) supplemented with 26.2 mM NaHCO\(_3\), 25 mM HEPES, 10 ml L\(^{-1}\) Glutamax (Gibco, USA), 10% fetal bovine serum (BioWest, France), 100 U ml\(^{-1}\) of penicillin/streptomycin (Sigma, Germany), and 100 µg/ml Geneticin (Gibco, UK).

The effect of AP14145 on K\(_{11.1}\) has previously been described (Dines et al., 2017). The same method has been applied to study the effect of dofetilide and ondansetron using a stable CHO-K1 cell line expressing K\(_{v11.1}\) on the automated QPatch machine. The cells were cultured in DMEM F12 (Sigma, USA), 10% fetal bovine serum (Biowest, France) and 100 µl ml\(^{-1}\) of penicillin/streptomycin (Sigma, Germany), 100 µg/ml Geneticin (Gibco, UK), 100 µg/ml hygromycin (Sigma-Aldrich), and 2 mM glutamine (Gibco, UK).

On the day of experiment, when cells reached about 70–90% confluency, they were detached with Detachin (Genlantis, USA) and resuspended in serum free medium (C5467 SAFC, Switzerland) containing 25 mM HEPES, 0.04 mg/ml soy bean trypsin inhibitor (T6522 Sigma-Aldrich), and 100 U/ml penicillin/streptomycin and were kept in suspension for QPatch experiments.

**Recordings and Data Analysis**

Manual patch clamp recordings were made using a HEKA EPC9 amplifier and the PatchMaster software (HEKA Elektronik, Germany) at room temperature using the whole cell configuration. Fluorescence was used to detect successfully transfected cells. Patch pipettes were pulled using a horizontal DMZ Universal Puller (Zeitz, Germany). I\(_{KCa}\) was elicited every 2 s using a 200-ms voltage ramp ranging –80 to +80 mV from a holding potential of 0 mV.

Automated patch-clamp whole-cell recordings were performed using a QPatch 16 HT system and disposable single-hole QPlates (Sophion, Denmark). Data were sampled at 10 kHz, four-order Bessel filter, cut-off frequency 3 kHz, and 80% Rs compensation. I\(_{KCa}\) was elicited by a linear voltage ramp from –80 to +80 mV (200 ms in duration) applied every fifth second. The holding potential was 0 mV. Recordings were made before and after application of drug. The amount of inward current at –80 mV is used and plotted as a function of time to generate an I/t plot.

CHO cells expressing K\(_{11.1}\) were held at –90 mV, and I\(_{KCa}\) was elicited by stepping to +20 mV for 2 s and then to –50 mV for 2 s. This second repolarizing step generates an outward tail current resulting from the recovery from inactivation. This tail current was plotted as function of time to generate an I/t plot.

For I\(_{KCa}\) and I\(_{Kr}\), the mean of the last three data points was used for further analysis. The currents were normalized using the last recordings prior to compound application as baseline and the current levels recorded in the presence of the positive control substances methyl-bicuculline for I\(_{KCa}\) or dofetilide for K\(_{11.1}\) as reference for total inhibition of the channel. The normalized currents were then plotted as a function of drug concentration and fitted using the following equation on GraphPad Prism 7: \(Y = 100 \times (X \times \text{HillSlope}) / (EC50 - X \times \text{HillSlope}) + X \times \text{HillSlope}\), where Y is the normalized measured current, X is the logarithm of the dose of the tested drug, and IC\(_{50}\) the drug concentration needed to inhibit 50% of the current. Individual IC\(_{50}\) values were calculated for each experiment and then used to obtain the final mean ± S.E.M.

Correction for baseline drift was applied if applicable using the QPatch software.

**Quantitative Polymerase Chain Reaction**

Five female Dunkin Hartley guinea pigs weighing 350–450 g were anesthetized and the hearts were quickly excised. The right atrium and left ventricle were separated and snap frozen in liquid nitrogen and kept at –80°C until RNA extraction.

Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Manchester, UK) and was quantified using a NanoDrop spectrophotometer (NanoDrop, Thermo Scientific, Wilmington, USA). The RNA was reverse-transcribed using the nanoScript kit (Primerdesign Ltd., Southampton, UK). Negative controls (RT-) were made in the absence of the nanoScript2 enzyme and no template controls (NTCs) were run simultaneously with all reactions to assess contamination. All reactions were performed in duplicates using PrecisionPLUS 2xqPCR MasterMix (Primerdesign Ltd.) with Precision Bright White real-time PCR 96-well plates on the CFX Connect Real-Time System (Bio-Rad, Hertfordshire, UK). The cycling conditions were: initial activation at 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, and 60°C for 1 min, and data were collected during each cycling phase. Cycle threshold (Ct) values were determined using Bio-Rad CFX96 Manager 3.0 software and the single threshold mode. Using a guinea pig genNorm Reference Gene Selection Kit (Primerdesign Ltd.), the genNorm software the best reference genes and number of reference genes required for the most accurate gene normalization were determined (Vandesompele et al., 2002). The optimal number of reference genes was two (where genNorm V < 0.15): ACTB and SDHA. The relative expression of the genes of interest (KCNN1, KCNN2, KCNN3, and KCNH2) was calculated...
relative to the mean expression levels of the reference genes (ACTB and SDHA) using 2−ΔΔct method (Livak and Schmittgen, 2001). All primers were double-dye (TaqMan style) and designed and optimized by Primerdesign Ltd. Primer sequences for guinea pig (Primerdesign Ltd.) are shown in Supplementary Table 1.

**Isolated Langendorff-Perfused Heart Preparations**

The Langendorff perfused heart experiments were performed using a total of 24 female Dunkin Hartley guinea pigs (350–450 g, Charles River, Saint-Germain-Nuelle, France). Guinea pigs were anesthetized with an i.p. injection of pentobarbital 200 mg/ml, lidocaine hydrochloride 20 mg/ml, (Glostrup Apotek, Denmark), dose 0.150 ml/10 g body weight.

A tracheotomy was performed and the guinea pigs were ventilated with 60 strokes*5 ml/min using a rodent ventilator (7025 Rodent ventilator, Ugo Basile, Italy). The hearts were excised and cannulated in situ through a small puncture of the aorta and connected to the Langendorff retrograde perfusion setup (Hugo Sachs Elektronik, Harvard Apparatus GmbH, March, Germany). The hearts were retrogradely perfused at a constant perfusion pressure of 60 mmHg at 37°C, pH 7.4, Krebs-Henseleit buffer (in mM: NaCl 120, NaHCO3 25, KCl 4, MgSO4 0.6, NaH2PO4 0.6, CaCl2 2.5, glucose 11) saturated with 95% O2 and 5% CO2. The aortic perfusion pressure was determined with an ISOTEC transducer (Hugo Sachs Elektronik) and the coronary flow was measured with an ultrasonic flow meter (Transonic Systems Inc., USA). Both were connected to an amplifier (Hugo Sachs Elektronik). The electrical activity was measured using volume conducted ECGs and by placing epicardial monophasic action potential electrodes (MAPs) on the atria and ventricles. The hearts were immersed into a temperature-controlled bath containing pH 7.4 Krebs-Henseleit buffer. Perfusion pressure, coronary flow, ECG, and MAP analogue signals sampled at a frequency of 2k/s and converted by a 16/30 data acquisition system from PowerLab systems (ADInstruments, Oxford, UK) and monitored using LabChart 7 software (ADInstruments).

A bipolar pacing electrode was placed on the right atrial appendage for epicardial pacing stimulation using square pulses of 2 ms durations at three times diastolic threshold at 300 beats per minute. During the entire experiment, the ECG was monitored and monophasic action potential electrodes were placed on each chamber of the heart. The hearts were then left to stabilize for 20 min at intrinsic heart rhythm. The right AERP was measured by 10 regular stimuli (S1) followed by a premature extra stimulus (S2) applied with 1-ms increments. The AERP was defined as the longest S1–S2 interval failing to elicit an action potential.

**Study Design**

Before each experiment isolated hearts were randomized to be perfused with AP14145, ondansetron, dofetilide, or vehicle (n = 6 for each group). After a period of stabilization, every Langendorff experiment consisted of four 20-min episodes (Figure 1). During the first 20-min episode, baseline parameters were recorded, and the following three 20-min episodes, the preparation was perfused with increasing concentrations of AP14145 (1, 10, and 30 µM), ondansetron (0.3, 1, and 3 µM) or dofetilide (3, 10, and 30 nM) or equivalent amounts of dimethylsulfoxide (DMSO) as the time matched control (TMC) group. During the entire experiment, the AERP was measured every 5 min and the ECG was continuously monitored.

**In Vivo Closed Chest Recordings**

A total of 18 female guinea pigs (Dunkin Hartley HsdPoc : GH, Charles River) weighing 350–450 g were anesthetized with 5% isoflurane/oxygen in a sedation box. The guinea pigs were placed under artificial ventilation through a cannula placed in the trachea and anesthesia was reduced to 2.5% isoflurane/oxygen throughout the experiment. The temperature of the guinea pigs was monitored with a rectal thermometer and kept stable during the experiment using a heating lamp. Needle ECG electrodes were placed in each limb for ECG recordings (ADInstruments, UK). An electrophysiological catheter with eight electrodes (EPR-802) (Millar Inc., US) was placed in the right atrium via the right jugular vein. The two electrodes proximal to the tip of the catheter (Heeringa et al., 2006; Piccini et al., 2012) were used to pace the atrium and six electrodes (Waldo et al., 1996; Redfern et al., 2003; Roukoz and Saliba, 2007; Piccini et al., 2009; Grunnet et al., 2012; Zimetsbaum, 2012) were used to measure the electrical activity in the atrium. The AERP was measured as in the Langendorff experiments. Between the AERP recordings, the heart remained unpaced. An intravenous catheter (inside diameter 0.5, outside diameter 0.8 mm, Natsume Seisakusho, Japan) was placed in the right jugular vein alongside the electrophysiology catheter for drug infusion.

**Study Design**

The animals were randomized to receive AP14145 (13.3 mg/kg, n = 6), dofetilide (0.01 mg/kg, n = 6), or vehicle (2.5 ml/kg, n = 6). First a period of 20 min baseline recording was conducted with AERP measurements every 5 min (Figure 1). After the baseline recording AP14145 (13.3 mg/kg), dofetilide (0.01 mg/kg), or vehicle was infused at a constant rate, over 20 min followed by a 20-min post-infusion period. The AERP was measured every 5 min during baseline and every 2 min during and after infusion.

**Data and Statistical Analysis**

The data and statistical analysis complies with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018). The operators in the ex vivo and in vivo experiments were not blinded to the treatment due to practical considerations. However, all data analysis was performed in a blinded fashion. ECG analyses were conducted in LabChart 7. Patch clamp recordings were acquired from PatchMaster and data analyses were performed using GraphPad Prism 7.0. Continuous data are summarized using the mean ± SEM. For the qPCR, two-tailed unpaired t-test was used to compare expression of the respective genes in atrium versus ventricle. Two-way ANOVA using Sidak’s post hoc test to compare differences in AERP, QTcB, and HR between the group receiving vehicle and groups receiving AP14145, ondansetron, or dofetilide. IXCa was normalized to cell capacitance and paired one-way ANOVA
FIGURE 1 | Flowchart of the Langendorff experiments (left) and in vivo closed chest recordings (right). See text for details.
with Dunnet’s post hoc test was performed to assess the effect of ondansetron and bicuculline methiodide. P values < 0.05 were considered significant and included in figures with three decimals.

RESULTS

Expression of Kv11.1 and Kca2.x Channels in Guinea Pigs

We performed qPCR to assess the expression levels of KCNN1 (KCa2.1), KCNN2 (KCa2.2), KCNN3 (KCa2.3), and KCNH2 (K11.1) mRNA in Dunkin Hartley guinea pigs. The guinea pigs showed a uniform expression of KCNN1, KCNN2, KCNN3, and KCNH2 in atria and ventricles (Figure 2).

In Vitro

A summary of IC50 values for ondansetron, dofetilide, and AP14145 on Kv11.1 and Kca2 channels published by our group previously or in the current study can be found in Table 1.

Effect of Ondansetron on Kca2 Channels

Cells were dialyzed with 400 nM intracellular calcium and Kca2.2 channels activated until IKCa reached a steady state. Then, 1 µM ondansetron was applied for at least 2 min, followed by 100 µM bicuculline methiodide to inhibit the remaining current. Surprisingly, and in contrast to recent studies (Ko et al., 2018), ondansetron failed to inhibit IKCa (n = 5, Figure 3).

These findings were also confirmed by whole cell automated patch clamp recordings on stable cell lines expressing KCa2.2 or KCa2.3, when increasing concentration of ondansetron was added (in µM: 0.1, 0.3, 1, 3, 10, and 30) giving IC50 values of >30 µM for KCa2.2 and KCa2.3, respectively (n = 8, Figure 4).

Ikr Is Inhibited by Dofetilide and Ondansetron But Not by AP14145

We have previously shown that the IC50 of AP14145 on Kv11.1 was: 71.8 µM (Diness et al., 2017), and in this study we confirm that dofetilide, which is a known Kv11.1 blocker, has an IC50 = 0.03 µM (n = 14) while ondansetron blocks Kv11.1 with an IC50 = 2.79 ± 0.03 µM (n = 6, Figure 5).

FIGURE 2 | The expression of KCNN1, KCNN2, KCNN3, and KCNH2 relative to the reference genes ACTB and SDHA using qPCR. No significant differences between the right atrium and the left ventricle are observed. Reactions were performed using tissue from five female Dunkin Hartley guinea pigs.

TABLE 1 | Summary of IC50 values for ondansetron, dofetilide, and AP14145 on Kv11.1 and Kca2 channels published by our group previously or in the current study.

| Ion channel | Method | AP14145 (IC50) | Dofetilide (IC50) | Ondansetron (IC50) |
|-------------|--------|---------------|-----------------|------------------|
| hKCa2.2     | Manual patch clamp | 1.1 µM (Simó-Vicens et al., 2017b) | >1 µM | |
| hKCa2.2     | Automated patch clamp | 1.1 µM (Simó-Vicens et al., 2017b) | 60 µM (Simó-Vicens et al., 2017a) | >30 µM |
| hKCa2.3     | Manual patch clamp | 1.3 µM (Diness et al., 2017) | 90 µM (Simó-Vicens et al., 2017a) | >30 µM |
| hKCa2.3     | Automated patch clamp | 71.8 µM (Diness et al., 2017) | 0.03 µM | 2.79 µM |
| Kv11.1      | Automated patch clamp | 1.1 µM (Simó-Vicens et al., 2017b) | |

Values with no reference are from the present study.
Effects on AERP, QTcB, and HR by AP14145, Ondansetron, and Dofetilide in Isolated Guinea Pig Hearts

In the Langendorff setup, AP14145 was added in increasing concentrations of 1, 10, and 30 µM to isolated guinea pig hearts. A significant AERP increase was observed at the end of wash-in with 10 µM compared to the vehicle TMC experiments (77 ± 2 ms vs. 61 ± 5 ms, P = 0.011). The AERP was further increased to a maximum of 93 ± 2 ms with 30 µM AP14145 compared to 64 ± 6 ms in the TMC group (P < 0.001). A concentration of 30 nM dofetilide increased AERP to 80 ± 4 ms compared to 64 ± 6 ms in the TMC group (P = 0.014). Ondansetron in concentrations up to 3 µM did not affect AERP significantly as compared to the TMC group (Figure 6A).

Dofetilide increased QTcB in concentrations of 10 and 30 nM to 306 ± 9 and 313 ± 9 ms, respectively, compared to TMC values of 271 ± 5 and 269 ± 6 ms (P < 0.001 in both cases). QTcB was also increased by 3 µM ondansetron to 294 ± 5 ms compared to the TMC value of 269 ± 6 ms (P = 0.005). AP14145 did not
affect QTcB in any of the concentrations tested. At the highest concentration of AP14145 the QTcB was 266 ± 4 compared to the TMC values of 269 ± 6 ms (Figure 6B).

Dofetilide concentrations of 10 and 30 nM caused a decrease in HR to 83 ± 3% and 80 ± 3% of baseline values, which was significantly different from the TMC group where HR was decreased to 94 ± 4% and 91 ± 4% of baseline values at the corresponding time points (P = 0.012 and P < 0.001, respectively). HR was also decreased by 30 µM AP14145 to 81 ± 3% of the baseline value, which was significantly different from TMC (P = 0.020). Ondansetron in concentrations up to 3µM did not significantly affect HR when compared to the TMC group (Figure 6C).

**Effects on AERP, QTcB, and HR by AP14145 and Dofetilide In Vivo**

In the *in vivo* guinea pig model, ECGs and atrial electrograms were recorded using needle electrodes and an intra-atrial catheter, respectively. After 6 min of infusion of AP14145 (at this time point 4 mg/kg had been given), the AERP was increased to 97 ± 6 ms compared to the TMC group in which AERP was 72 ± 2 ms (P < 0.001, Figure 7A).

AERP continually increased during the infusion of AP14145 to a maximum of 113 ± 6 ms compared to TMC (AERP = 75 ± 3 ms, P < 0.001). No effect on AERP of dofetilide infusion was observed.

As in the Langendorff experiments, no effect on QTcB with infusion of AP14145 was observed. In contrast, after 5 min of infusion the QTcB in the dofetilide group was increased to 319 ± 11 ms compared to the TMC group in which QTcB was 280 ± 9 ms (P < 0.031, Figure 7B). QTcB continually increased during the infusion of dofetilide to a maximum of 336 ± 16 ms compared to TMC (QTcB = 275 ± 10 ms, P < 0.001). During the infusion of AP14145 and dofetilide, the HR continuously declined to a minimum 5 min after the end of infusion. At this time point the HR in the AP14145 group and the dofetilide group was 83 ± 2% and 82 ± 3% of the baseline average and, respectively, which was in both cases lower than the HR of the TMC group, which was 93 ± 2% of the baseline average (P < 0.001, Figure 7C).

**DISCUSSION**

In this study it was compared how blocking two different K+ channels affects ventricular and atrial repolarization in guinea pigs. The effects of blocking the classical class III target, IKr, were examined with the specific IKr blocker dofetilide. The effects of inhibiting the relatively new anti-AF target, IKCa, were examined with the tool compound AP14145. Since ondansetron is a known IKr blocker and was recently claimed to also be a potent blocker of IKCa, this compound was additionally examined in isolated hearts (Ko et al., 2018).

**Effects of the IKCa Inhibitor AP14145**

The IKCa inhibitor, AP14145, prolonged AERP without increasing the QTcB interval, supporting the notion that IKCa inhibition is a promising atrial specific antiarrhythmic target.

We hypothesized that this chamber difference was caused by differential expression of KCa2 channels in the atria vs ventricles. However, our qPCR data did not confirm this since no chamber specific distribution of KCNN1 (KCa2.1), KCNN2 (KCa2.2), and KCNN3 (KCa2.3) were found on the transcriptional level. However, a number of posttranscriptional and post translational modifications may affect the actual protein levels. Furthermore, it can be speculated that differences between the precise subcellular location of the channels, action potential morphology, calcium dynamics, in atria and ventricles may affect activity of the channels and thus explain why IKCa plays a more crucial role in the atria than in guinea pig ventricles under physiological conditions.

The HR was decreased by AP14145 both *ex vivo* and *in vivo*, which is in line with previous findings that IKCa inhibition decreases sinoatrial activity (Chen et al., 2013; Torrente et al., 2017).

**Effects of the IKr Inhibitor Dofetilide**

The IKr inhibitor dofetilide increased both ventricular and atrial repolarization in the isolated heart preparation. More pronounced IKs and IKr currents have been reported in the
atria as compared to ventricles of guinea pigs (Sanguinetti and Jurkiewicz, 1991). However, surprisingly, ventricular repolarization was affected at lower concentrations of dofetilide than atrial repolarization. In vivo, dofetilide significantly prolonged the QTcB interval, but did not affect the AERP. Our functional data therefore suggest a more critical functional role of $I_{Kr}$ in the ventricles compared to the atria in the guinea pig, which is comparable to what is seen in humans, where $K_{v11.1}$ is more expressed in ventricles as compared to atria (Pond et al., 2000). The apparent functional ventricular selectivity of $I_{Kr}$ inhibition cannot be explained by the expression data as we did not find any chamber specific distribution of $KCNH2$ ($K_{v11.1}$) on guinea pig mRNA level using quantitative PCR. Again, the explanation for this could be found among posttranscriptional and posttranslational factor affecting the actual protein levels as well as differences in the action potential morphology, which will lead to different activation of the $K_{v11.1}$ channel in atria compared to ventricles.

The HR was decreased by dofetilide both ex vivo and in vivo in line with previous findings (Ruppert et al., 2016).
Effects of Ondansetron

Ondansetron was included in this study since it has been reported to block both I_{Kr} and I_{KCa} at nanomolar concentrations (Kuryshev et al., 2000; Ko et al., 2018). Ondansetron is known to prolong the QT interval in patients (Benedict et al., 1996; Boike et al., 1997). This has traditionally been ascribed to its I_{Kr} blocking properties (Kuryshev et al., 2000). The data in the present study do lend support to the notion that ondansetron affects cardiac repolarization by inhibiting I_{Kr}, but not by inhibiting I_{KCa}. In vitro the compound did not affect HEK cells expressing K_{Ca2.2} channels (IC_{50} > 30 µM).
The effects of AP14145 (13.3 mg/kg) or dofetilide (0.01 mg/kg) on AERP (A), QTcB (B), and heart rate (C) were investigated in closed chest atrially paced guinea pigs. P-values < 0.05 are given with three decimals in blue for AP14145, and red for dofetilide.
n = 8), nor K\(_{\text{Ca}}\)2.3 channels (IC\(_{50} > 30 \mu M \ n = 8\)) but it did inhibit I\(_{\text{Kc}}\) in CHO-K1 cells expressing K\(_{\text{Ca}}\)1.1 (IC\(_{50} = 2.79 \pm 0.03 \mu M \ n = 6\)). Furthermore, in the isolated guinea pig hearts, the profile of ondansetron was similar to dofetilide and not to AP14145.

K\(_{\text{Ca}}\)2 channels are widely expressed in the CNS and I\(_{\text{Kc}}\) inhibition is known to show neurological side effects in form of tremors when tested in conscious animals, probably due to the compound crossing the blood–brain barrier and blocking the neuronal K\(_{\text{Ca}}\)2 channels (Stocker and Pedarzani, 2000; Simó-Vicens et al., 2017a). Avoiding CNS mediated adverse effects when developing compounds targeting peripheral K\(_{\text{Ca}}\)2 channels would therefore be prudent. Indeed, changes in tremorography data are part of the primary tolerability/safety endpoints in the first clinical study with an I\(_{\text{Kc}}\) inhibitor, AP30663 (CHDR1706). If the CNS active compound ondansetron does indeed inhibit I\(_{\text{Kc}}\), it would be expected to cause tremors, which does not seem to be the case in patients treated for nausea and vomiting.

### Isolated Heart Preparation vs Closed Chest Preparation

AERP prolongation can translate to antiarrhythmic effect and is therefore a useful parameter in the development of antiarrhythmic compounds (Nattel, 2002; Comtois et al., 2005). The Langendorff model is a thoroughly validated model for measurements of AERP and QTcB. However, as the heart is excised from the body important neuro- and hormonal regulation of the heart is lost. This could potentially limit its usefulness as a tool for screening for novel antiarrhythmic drugs. In our experiments with AP14145 and dofetilide we found similar results for the Langendorff perfused heart experiments and closed chest recordings. This suggests that the isolated perfused heart preparation and the closed chest guinea pig model are equally suitable for evaluating AERP and QTcB effects of new chemical entities.

### Limitations

The sample size for most of the experiments in the current study is relatively small (n = 5 or 6) which increases the risk of making a type II error (wrongfully concluding that there is no difference between two samples). Thus, the study was only powered to detect relatively large and/or uniform differences between groups.

### CONCLUSION

In contrast to dofetilide and ondansetron, I\(_{\text{Kc}}\) inhibition by AP14145 increased AERP without prolonging QTcB in both Langendorff and a novel closed-chest guinea pig model. The data support that SK inhibition has the potential to be an effective approach in the treatment of AF.

Good consistency was observed between results obtained in isolated Langendorff hearts and in the novel in vivo guinea pig model.

### ETHICS STATEMENT

This study was performed under a license from the Danish Ministry of Justice (license no 2016-15-0201-00850) and in accordance with the recommendations of the Danish guidelines for animal experiments according to the European Commission Directive 86/609/EEC. The protocol was approved by the Danish Ministry of Justice.

### AUTHOR CONTRIBUTIONS

JK, MS, KM, RS-V, SB, and LA performed the research. JD and BB designed the research study. US, MG, BB, and TJ contributed essential reagents or tools. JK, MS, RS-V, SB, and JD analyzed the data. JK and JD wrote the paper.

### FUNDING

This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 675351 and the Innovation Fund Denmark.

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.00668/full#supplementary-material

### REFERENCES

Benedict, C. R., Arborgast, R., Martin, L., Patton, L., Morrill, B., and Hahne, W. (1996). Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J. Cardiovasc. Pharmacol. 28, 53–59. doi: 10.1097/00005344-199607000-00009

Boiße, S. C., Ilson, B., Zariffa, N., and Jorkasky, D. K. (1997). Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am. J. Health Syst. Pharm. 54, 1172–1176. doi: 10.1093/ajhp/54.10.1172

Boîte, D. K. (1997). Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am. J. Health Syst. Pharm. 54, 1172–1176. doi: 10.1093/ajhp/54.10.1172

Boîte, D. K. (2000). Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am. J. Health Syst. Pharm. 54, 1172–1176. doi: 10.1093/ajhp/54.10.1172

Boîte, D. K. (2005). Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am. J. Health Syst. Pharm. 54, 1172–1176. doi: 10.1093/ajhp/54.10.1172

This is a randomised, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects [Internet]. [cited 2018 Sep 19]; Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7012.

This is a randomised, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects [Internet]. [cited 2018 Sep 19]; Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7012.

This is a randomised, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects [Internet]. [cited 2018 Sep 19]; Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7012.
of small-conductance Ca2+-activated k+ channels in pigs. Circ. Arrhythm. Electrophysiol. 10, p. e005125. doi: 10.1161/CIRCEP.117.005125
Ellinor, P. T., Luna, K. L., Glazer, N. L., Pleuter, A., Alonso, A., Chung, M. K., et al. (2010). Common variants in KCNJ3 are associated with lone atrial fibrillation. Nat. Genet. 42, 240–244. doi: 10.1038/ng.537
Ellinor, P. T., Lunetta, K. L., Albert, C. M., Glazer, N. L., Ritchie, M. D., Smith, A. V., et al. (2012). Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet. 44, 670–675. doi: 10.1038/ng.2261
Grunnet, M., Bentzen, B. H., Sorensen, U. S., and Dines, J. G. (2012). Cardiac ion channels and mechanisms for protection against atrial fibrillation. Rev. Physiol. Biochem. Pharmacol. 162, 1–58. doi: 10.1007/112_2011_3
Heeringa, J., Conway, D. S. G., van der Kuip, D. A. M., Hofman, A., Breteler, M. M. B., Lip, G. Y. H., et al. (2006). A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J. Thromb. Haemost. 4, 1944–1949. doi: 10.1111/j.1538-8836.2006.02115.x
Ko, J.-S., Guo, S., Hassel, J., Celestino-Soper, P., Lynnes, T. C., Tisdale, J. E., et al. (2018). Ondansetron blocks wild-type and p.F503L variant small-conductance Ca2+-activated k+ channels. Am. J. Physiol. Heart Circ. Physiol. 315, H375–H388. doi: 10.1152/ajpheart.00479.2017
Kuryshev, Y. A., Brown, A. M., Wang, L., Benedict, C. R., and Rampe, D. (2000). Interactions of the 5-hydroxytryptamine 3 antagonist class of antiepileptic drugs with human cardiac ion channels. J. Pharmacol. Exp. Ther. 295, 614–620.
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method. Methods 25, 402–408. doi: 10.1006/meth.2001.1262
Nattel, S. (2002). New ideas about atrial fibrillation 50 years on. Nature 415, 219–226. doi: 10.1038/415219a
Piccini, J. P., Whellan, D. J., Berridge, B. R., Finkle, J. K., Pettit, S. D., Stockbridge, N., et al. (2009). CSCRC/HESI Writing Group. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am. Heart J. 158, 317–326. doi: 10.1016/j.ahj.2009.06.007
Piccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N. H., Hernandez, A. F., Heckbert, S. R., et al. (2012). Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ. Cardiovasc. Qual. Outcomes 5, 85–93. doi: 10.1161/CIRCOUTCOMES.111.962688
Pond, A. L., Scheve, B. K., Benedict, A. T., Petrecca, K., Van Wagoner, D. R., Shier, A., et al. (2000). Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to functional L(Kr) channels. J. Biol. Chem. 275, 5997–6006. doi: 10.1074/jbc.275.8.5997
Qi, X.-Y., Diness, J. G., Grunnet, M., Bentzen, B. H., Sorensen, U. S., et al. (2017b). A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium channels. Eur. J. Pharmacol. 803, 118–123. doi: 10.1016/j.ejphar.2017.03.039
Simó-Vicens, R., Sauter, D. R. P., Simó-Vicens, R., Kirchhoff, J. E., Dolce, B., Abildgaard, L., Speerschneider, T., Sorensen, U. S., et al. (2017b). A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (KCa 2) channels. Br. J. Pharmacol. 174, 4396–4408. doi: 10.1111/bph.14043
Sanginetti, M. C., and Jurkiewicz, N. K. (1991). Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells. Am. J. Physiol. 259, H339–H349. doi: 10.1152/ajpheart.1991.259.2.H343
Simó-Vicens, R., Santer, D. R. P., Grunnet, M., Diness, J. G., and Bentzen, B. H. (2017a). Effect of antiarrhythmic drugs on small conductance calcium-activated potassium channels. Eur. J. Pharmacol. 803, 118–123. doi: 10.1016/j.ejphar.2017.03.039
Simó-Vicens, R., Kirchhoff, J. E., Dolce, B., Abildgaard, L., Speerschneider, T., Sorensen, U. S., et al. (2017b). A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (KCa 2) channels. Br. J. Pharmacol. 174, 4396–4408. doi: 10.1111/bph.14043
Stockner, M., and Pedarzani, P. (2000). Differential distribution of three Ca2+-activated K+ channel subunits, SK1, SK2, and SK3, in the adult rat central nervous system. Mol. Cell. Neurosci. 15, 476–493. doi: 10.1006/mcne.2000.0842
Strobaek, D., Teuber, L., Jørgensen, T. D., Ahirng, P. K., Kjaer, K., Hansen, R. S., et al. (2004). Activation of human IK and SK Ca2+-activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim. Biophys. Acta. 1665, 1–5. doi: 10.1016/j.bbagen.2004.07.006
Torrone, A. G., Zhang, R., Wang, H., Zaini, A., Kim, B., Yue, X., et al. (2017). Contribution of small conductance K+ channels to sinoatrial node pacemaker activity: insights from atrial-specific Na+-/Ca2+ exchange knockout mice. J. Physiol. (Lond.) 595, 3847–3865. doi: 10.1113/JP274249
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, research0034.1-0034.11. doi: 10.1186/gb-2002-3-7-research0034
Waldo, A. L., Camb, A. J., deRuyter, H., Friedman, P. L., MacNeil, D. J., Pauls, J. P., et al. (1996). Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-Sotalol. Lancet 348, 7–12. doi: 10.1016/S0140-6736(96)2149-6
Xu, Y., Tuteja, D., Zhang, Z., Xu, D., Zhang, Y., Rodriguez, J., et al. (2003). Molecular identification and functional roles of a Ca2+-activated K+ channel in human and mouse hearts. J. Biol. Chem. 278, 49085–49094. doi: 10.1074/jbc.M307508200
Zimtambaum, P. (2012). Antiarrhythmic drug therapy for atrial fibrillation. Circulation 125, 381–389. doi: 10.1161/CIRCULATIONAHA.111.019927

Conflict of Interest Statement: JD, US, MG, and BB are used by and have interests in Acesion Pharma and are inventors of Acesion Pharma patents within the field of SK channels.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Kirchhoff, Skarsfeld, Matlikumarasamy, Simó-Vicens, Bomholte, Abildgaard, Jøpersen, Sorensen, Grunnet, and Bentzen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.